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component highly expressed in early stages, and common to normal and
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Summary The melanosome is a secretory organelle unique to the melanocyte and its neoplastic counterpart,
malignant melanoma. The synthesis and assembly of these intracytoplasmic organelles is not yet fully
understood. We have developed a murine monoclonal antibody (MoAb) against melanosomes isolated from
human melanocytes (newborn foreskin) cultured in the presence of 12-0 tetradecanoyl phorbol-13-acetate
(TPA). This MoAb, designated HMSA-5 (Human Melanosome-Specific Antigen-5) (IgG1), recognised a
cytoplasmic antigen in both normal human melanocytes and neoplastic cells, such as common and dysplastic
melanocytic nevi, and malignant melanoma. None of the carcinoma or sarcoma specimens tested showed
positive reactivity with MoAb HMSA-5. Under immunoelectron microscopy, immuno-gold deposition was
seen on microvesicles associated with melanosomes, and a portion of the ER-Golgi complexes. Radioimmuno-
precipitation analysis showed that the HMSA-5 reactive antigen was a glycoprotein of M, 69 to 73 kDa. A
pulse-chase time course study showed that the amount of antigen detected by MoAb HMSA-5 decreased over
a 24 h period without significant expression on the cell surface, or corresponding appearance of the antigen in
the culture supernatant. This glycoprotein appears to play a role in the early stages of melanosomal
development, and the HMSA-5 reactive epitope may be lost during subsequent maturation processes. Impor-
tantly, HMSA-5 can be identified in all forms of human melanocytes, hence it can be considered a new
common melanocytic marker even on routine paraffin sections.
Human melanocytes migrate from the neural crest into the
skin during the first 6 to 8 weeks of embryonic development.
During the process of differentiation melanocytes sythesise
unique secretory granules, the melanosomes, which are
known to contain structural matrix proteins, lipids, melanin,
tyrosinase, and some post-tyrosinase regulatory factors
(PTRF) (Jimbow, 1986). Mechanisms involved in the syn-
thesis and assembly of these melanosomal constituents have
not yet been definitively elucidated. However, an understand-
ing of these processes may be important in determining the
molecular events involved in normal melanisation. It may be
equally important for an explanation as to why melanosomes
found in melanoma cells and their precursors exhibit
markedly aberrant morphology (Takahashi et al., 1985).
Since a major role of the melanosome is to contain the
otherwise toxic and/or tumour-promoting chemical inter-
mediates of melanogenesis (Jimbow, 1986), any process which
compromises the structural integrity or correct functioning of
the melanosome could have serious consequences to the cell.
Previous studies have shown that melanosomes isolated from
neoplastic melanocytes express unique antigenic deter-
minants, such as those detected by monoclonal antibodies
(MoAbs) HMSA-1 and 2 (Akutsu & Jimbow, 1986; Maeda
& Jimbow, 1988). At the molecular level, changes responsible
for the malformation may be genetic abnormalities found in
transformed cells (Jimbow et al., 1988). Progressive aneu-
ploidy and non-random chromosomal abnormalities involv-
ing chromosomes 1, 6 and 7 have been frequently found in
melanoma cells (Bale et al., 1989; Herlyn et al., 1987; Herlyn
et al., 1985; Nowell, 1989). These changes may result in
aberrant expression of gene(s) involved in the biosynthesis of
melanosomal constituents, which may lead directly or
indirectly to alterations in the structure and/or assembly of
melanosomes. Disturbed rates of transcription and putative
alternative splicing of mRNAs have also been reported in
tumour cells and may contribute to the melanosomal
derangement. In addition, signals targeting the transport of
proteins to intracellular organelles (Garcia et al., 1988) may
be disturbed due to altered co- and/or post-translational
modifications. In order to substantiate such putative patho-
physiological processes, a comparison of melanosomal con-
stituents found in normal and neoplastic melanocytes is
required. We have shown previously that murine MoAbs
HMSA-1 and HMSA-2 recognise epitopes on structural mat-
rix proteins highly specific to melanosomes of neoplastic
human melanocytes (Akutsu & Jimbow, 1986; Maeda &
Jimbow, 1988). In the present study, we have developed a
new murine MoAb, designated HMSA-5 (IgG,), against
melanosomes isolated from human melanocytes of newborn
foreskin, grown in the presence of TPA. We found that
MoAb HMSA-5 reacted with normal and neoplastic melano-
cytes on both paraffin and frozen specimens. Immunoelectron
microscopy and immunoprecipitation studies suggested that
the HMSA-5 antigen may be a precursor molecule of a
melanosomal constituent, associated with microvesicles which
give rise to, or fuse with melanosomes, and that the HMSA-5
reactive epitope is lost during the melanosomal differ-
entiation.
Materials and methods
Cells
Human melanocytes Human melanocytes (108) were ob-
tained from newborn foreskin and grown under the condi-
tions reported by Eisinger and Marko (1982). Briefly, new-
born foreskins were incubated in a trypsin solution, 0.25%
(w/v) (Gibso, Grand Island, NY), 12 h at 4'C. The epidermis
was then gently peeled from the dermis. The epidermal sheet
was vigorously pipetted until a single cell suspension was
generated. The suspension was centrifuged and the pellet was
resuspended in culture medium supplemented with TPA
(Sigma Chemical Co., St. Louis, Mo), 1Ongml-', and 7.5%
(v/v) of foetal calf serum (FCS, Gibco, Grand Island, NY). If
fibroblast contamination was found to be present, a single
dose of geneticin, 100ligml-' was added to the medium
(usually at 3-4 weeks).
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Melanoma cells Cultured cells of five melanoma cell lines
were used in this study. These included G361 (ATCC-1640),
HMV II (kindly supplied by Dr T. Kasuga, Tokyo Medical
and Dental School, Tokyo, Japan) and SK-Mel 23, SK-Mel
28 and SK-Mel 118 (kindly supplied by Dr A. Houghton,
Sloan Kettering Cancer Center, NY).
Enzymes
N-Glycanase (peptide: N-glycosidase F,E.C. 3.2.2.18) was
obtained from Genzyme (Boston, MA). Trypsin (sequencing
grade E.C. 3.4.21.4) and V8 protease (endoproteinase glu-C,
E.C. 3.4.21.29) were obtained from Boehringer Mannheim
(Dorval, Quebec).
Antibodies
Monoclonal antibody MoAb TA99 (Mel-5) was obtained
from Signet Laboratories Inc., Dedham, MA, and has been
described previously (Thomson et al., 1985). Normal mouse
serum conjugated to cross-linked agarose was obtained from
Sigma Chemical Co., St. Louis, Mo. Polyvalent goat anti-
mouse antibody was purchased from Cappel, West Chester,
PA.
Chemicals and radiochemicals
Tunicamycin and monensin were obtained from Sigma and
were dissolved in DMSO (10 mgml-') and 95% (v/v) eth-
anol (10 mM) respectively. Deoxynojirimycin and swainsonine
were obtained from Boehringer Mannheim, Dorval, Quebec
and were dissolved in a sterile water at 10mgml-' and
500jigml-I respectively. Brefeldin A was obtained from Bio/
Can Scientific, Mississauga, Ontario and was dissolved in
95% (v/v) ethanol at 10 mgml'. '25I-sodium iodide (506.9
MBqfig-') was obtained from Amersham (Oakville, Ontario)
and L-35S-methionine (29.6 TBq mmol-1) was from NEN/
DUPONT (Mississauga, Ontaria).
Development ofmonoclonal antibody
Immunogen Approximately 8 x 107 cultured human melano-
cytes were collected and stored at - 90°C. These cells were
homogenised in 0.05M phosphate buffer, pH 6.8, supple-
mented with 0.25 M sucrose, 20 mM KCI, 4mM MgCl2, and
1 mM phenylmethyl-sulfonyl fluoride (PMSF). Melanosomes
were isolated from an homogenate of these cells by a discon-
tinuous sucrose density gradient ultracentrifugation proce-
dure as described previously (Jimbow et al., 1988). The purity
of the melanosomal fraction was examined by both light and
electron microscopy.
Immunisation The purified human melanosomes were re-
suspended in phosphate buffered saline (PBS), at an approx-
imate concentration of 1.5 mg ml-', sterilised by irradiation
with a bacteriostatic dose of 2,500 rad, emulsified with 1.5 ml
Freund's complete adjuvant (Gibco, Grand Island, NY), and
injected subcutaneously into BALB/c mice (6 to 8 weeks old,
female). After three boost injections at 2 week intervals, a
test bleed was carried out. The test serum showed a positive
reaction with melanocytes cultured in 96 microwell plates at
a dilution of 1 in 10,000 with avidin biotin immunoperox-
idase complex (ABC) stain (Vectastain ABC kit, Vector
Laboratories, Burlingham, CA). A clone, HMSA-5, was
selected from a fusion of the immunised splenocytes with
murine myeloma cells (Sp2/0), at a 1 to 5 ratio, following a
published hybridoma fusion/selection protocol (Eager &
Kennet, 1983). For screening of the hybridoma clones,
melanocytes cultured in 96 microwell plates (Costar, Cam-
bridge, MA) and paraffin-embedded sections of normal
human skin were stained with cultured hybridoma super-
natant, using the ABC method.
Immunostaining
Paraffin embedded sections were deparaffinised in xylene, and
rehydrated in a graded series of alcohol solutions. The
endogenous peroxidase activity was blocked by incubating
sections with 0.3% (v/v) hydrogen peroxide in absolute
methanol for 30 min. Sections were washed in PBS and
blocked with 1% (w/v) bovine serum albumin (BSA) for
30 min. After a 2 h incubation with hybridoma-culture
superntant, sections were washed in PBS and incubated with
the biotinylated horse anti-mouse IgG antibody for 1 h. Sec-
tions were washed in PBS for 5 min, incubated for 1 h with
ABC and the products of the reaction were detected using
diamino-benzidine (DAB) as described previously (Akutsu &
Jimbow, 1986).
Radiolabelling
In vivo biosynthesis labelling Melanoma cells, G361 or SK
Mel-23 (1 x 106), in exponential growth phase were cultured
in methionine-free media (Select-amine, Gibco, Grand Island,
NY) for 2 h, and incubated with medium containing 35S-
methionine (0.5 mCi, Amersham, Arlington Heights, Il), in
5% (v/v) CO2 at 37°C, for 12 h. Cells were harvested by
scraping and the cell pellet was lysed with a lysis buffer
consisting of 1 mM MgCl2, 0.25% Trasylol (Sigma Chemical
Co. St. Louis, Mo), 1% (v/v) NP-40 0.1% (w/v) sodium
azide, and 10 mM PMSF in 10 mM Tris-HCl, pH 7.6, for
30 min on ice and processed for immunoprecipitation. When
inhibitors of glycosylation/intracellular transport were used
for metabolic labelling studies, the cells were pre-incubated
with the inhibitors for 6 h and the same concentrations of
inhibitors were maintained during the labelling incubation
itself. The final concentrations of the inhibitors which were
used are described in the figure legends.
In vitro cell surface labelling To a suspension (1 ml) of
G361 melanoma cells (5 x 106 cellsml-') 0.5mCi of 1251_
sodium iodide was added, and placed on ice. The suspension
was then transferred to lodo-gen coated tubes (Pierce,
Terochem, Edmonton, Alberta) and incubated for 5 min on
ice. The reaction was terminated by transferring the labelled
cell suspension to cold sodium iodide (1 mM) containing
media and washed by three successive rounds of centrifuga-
tion and resuspension in fresh cold media.
Labelling ofcell lysates Alternatively, the cell pellet of G361
melanoma cells (5 x 106) was incubated with 1 ml lysis buffer
(1 ml) for 30 min at 4°C. The lysate was centrifuged
(16,000g, 30 min) and transferred to a fresh tube, to which
'251I-sodium iodide (0.5 mCi) was added The labelling mixture
was then transferred to an lodo-gen coated tube, incubated
for 5 min on ice, and applied to a PD-10 column (Pharmacia,
Baie D'Urfe, Quebec), pre-equilibrated with a wash buffer
(0.5M NaCl, 5 mM EDTA 1% [w/v] NP 40 and 1% [v/v]
FCS in 50 mM Tris HCl, pH 7.5). Radiolabelled protein was
eluted from the column with the same buffer (without FCS)
and fractions were collected (1.0 ml/fraction) and aliquots
counted by liquid scintillation counting. The radioactive pro-
tein peak fractions were pooled and processed for immuno-
precipitation.
Immunoprecipitation
The supernatants of cell lysates (from in vivo biosynthetic
labelling of cell surface iodination or from whole cell lysate
iodination) were diluted to 10 ml with heat-inactivated FCS
solution supplemented with 0.25% (v/v) Trasylol, 0.1% (w/v)
sodium azide, 10 mM PMSF and 1% (v/v) NP-40. The
diluted mixtures were precleared with pre-immune mouse
serum agarose beads (Sigma Chemical Co., St. Louis, Mo),
50gl of 50% (w/v) suspension three times and then with
protein-A Sepharose (Pharmacia, Baie D'Urfe, Que), 50 "l of
50% (w/v) suspension. The precleared lysates were then
incubated with cultured supernatant (50 1) or purifiedHUMAN MELANOSOME SPECIFIC ANTIGEN (HMSA) 49
antibody (10 lI) by end-over-end rotation at 4°C for 10h,
followed by incubation with a polyvalent goat anti-mouse
antibody (Cappel, West Chester, PA), 10lyI for 4h, and
finally with protein-A Sepharose beads, 501il for 2h. The
beads containing the immune complex were washed with
wash buffer I (0.5 M NaCl, 5 mM EDTA, 1% [v/v] NP-40, in
50 mM Tris-HCI, pH 7.5), 10 ml, four times, and with wash
buffer II (0.5 M NaCl and 5 mM EDTA in 50 mM Tris-HCI,
pH 7.5) 10ml, twice. The samples were boiled for 5 min in
SDS-PAGE sample buffer and resolved on 15% (w/v)
polyacrylamide gels (SDS-PAGE) (Laemmli, 1970). For semi-
quantitative studies, cell lysates were balanced for radioactive
content. Briefly, aliquots of the cell lysates (20 1l) were
precipitated with 25% (w/v) TCA (5 ml), on ice for 30 min,
absorbed on filter paper and processed for liquid scintillation
counting. Aliquots of cell lysates with equal radioactivity
were processed for immunoprecipitation.
Biosynthetic labelling studies
Pulse chase time course Following a 2 h methionine deple-
tion, G361 melanoma cells were pulse-labelled for 30min
with media containing 35S-methionine. The radioactive media
was then removed and replaced with unlabelled culture
medium and the cells were incubated for various times. Cells
were harvested at 0, 0.25, 0.5, 1, 2, 5, 16 and 24 h time
intervals during the chase period, and processed for immuno-
precipitation with MoAb HMSA-5 as described above, and
resolved on 15% SDS-PAGE gels (Laemmli, 1970).
Sequential immunodepletion study
An 35S-labelled lysate ofG361 melanoma cells was precleared
four times with normal mouse serum agarose and once with
protein A-Sepharose as described above, and divided into
two identical aliquots. One aliquot was subjected to four
sequential rounds of immuno-precipitation with HMSA-5
culture supernatant (50fl per round) as described above,
followed by one round with the secondary antibody alone to
absorb any residual HMSA-5 immune complexes. The super-
natant from this last step was then immunoprecipitated with
MoAb TA99 (10 tli purified MEL-5, Signet Labs.). The other
aliquot was processed similarly, except MoAb TA99 was
used for the initial four rounds of immunoprecipitation fol-
lowed by a final round with MoAb HMSA-5. The resulting
immunoprecipitates were analysed on SDS-PAGE gels as
described below.
Glycosylation studies
N-glycanase digestion The HMSA-5 immunoprecipitate was
washed end-over-end with wash buffer I and II at 4°C, and
then boiled in 0.5% SDS for 3 min. Aliquots of the SDS-
glycoprotein solution (201tl) were diluted and incubated with
N-Glycanase (Genzyme Corporation, Boston, MA) accord-
ing to the manufacturer's recommendations for 0.25, 0.75,
1.5, 3, 8 and 16 h at 37°C. The reaction was stopped by the
addition of SDS-PAGE sample buffer and the samples were
boiled for 5 min and processed for SDS-PAGE analysis. A
control digestion was carried out under identical conditions
for the longest time period without the addition of enzyme.
Trypsin digestion
"S-labelled lysates of cultured melanoma cells (2 x 106) were
immunoprecipitated using culture supernatant of MoAb
HMSA-5 (20 gil) or purified MoAb TA99 (Signet Lab Inc.
Dedham, MA; 10 I of a 1 in 30 dilution) as described above.
The resulting immunoprecipitates were washed with wash
buffers I and II and boiled in 1% SDS, for 5 min. SDS
glycoprotein supernatant (50jil) was mixed with 50IlI of
0.1 M Tris-HCI, pH 8.5, and then treated with 5p1 of trypsin
suspended in 10p1l of 1 mM HCI. The reaction was stopped
by the addition of SDS-PAGE sample buffer and the samples
were prepared for SDS-PAGE analysis.
V8protease digestion
Immunoprecipitates of HMSA-5 and TA99 were resuspended
in V8 protease sample buffer containing 0.1% (w/v) SDS,
1 mM EDTA, 2.5 mM DTT in 125 mM Tris-HCI, pH 6.8 and
boiled for 5 min. Glycerol was added to a final concentration
of 20% (w/v) and the sample supernatants were transferred
to the wells of an SDS-PAGE gel to which 1 mM EDTA had
been added and which had a stacking gel at least 3 cm in
depth. The sample was overlayered with 10pLI of 10%
glycerol, 0.1% (w/v) SDS, 1 mM EDTA, 2.5 mM DTT and
0.001% bromophenol blue (BPB) in 125 mM Tris-HCl,
pH 6.8, containing 0.05, 0.5 and 5 fig of V8 protease. Electro-
phoresis was continued until the BPB marker had migrated
2 cm into the stacking gel, after which the power was turned
off and the protein was allowed to digest for 30 min. The
power was restored and the electrophoresis was continued
until the BPB marker had reached the end of the separating
gel (Harlow & Lane, 1988). The gel was processed for
fluorography to analyse the resulting peptide fragments.
Gelelectrophoresis
Immunoprecipitates were resuspended in Laemmli sample
buffer (two volumes) (Laemmli, 1970). The samples were
boiled for 5 min, cooled, and loaded on SDS-PAGE gels
containing a 5% (w/v) acrylamide stacking gel and a 15%
(w/v) acrylamide separating gel. 14C-Labelled molecular
weight standards (Amersham, Arlington Heights, IL) were
used to calibrate the size of proteins. The markers included:
myosin (200 kDa), phosphorylase b (100 and 92.5 kDa),
bovine serum albumin (69 kDa), ovalbumin (46 kDa), car-
bonic anhydrase (30 kDa) and lysozyme (14.3 kDa). Gels of
'25I-samples were fixed with water:methanol:acetic acid
(68:25:7 by volume) and processed for autoradiography
whereas 35S-methionine containing gels were processed for
fluorography (Laskey & Mills, 1975).
Immunoelectron microscopy
Subconfluent, monolayer cultures of G361 melanoma cells
were washed with PBS, fixed in 4% paraformaldehyde in
0.1 M PBS, pH 7.2, for 45 min. After PBS wash the cells were
incubated with 0.2% saponin, for 30 min and then blocked
with 1% BSA, and incubated with the primary antibody for
2 h. Cells were washed with PBS and incubated with protein
A-gold (5 nm in particle size) (Janssen Biotech N.V., Olen,
Belgium) (1 in 50 dilution) for 60min. They were postfixed
with 2.5% glutaraldehyde for 30 min, and osmium tetroxide
for 60min, dehydrated and then embedded in LX-112 resin
(Ladd Research Industries, Inc. Burlington, Vermont). Ultra-
thin sectioning was carried out with a MT-2 Porter Blum
ultratome. Sections were examined under a Siemens Elmin-
skop 101.
Results
Immunohistochemical study
Normal tissues MoAb HMSA-5 reacted strongly with
epidermal melanocytes in both newborn and adult skin of
frozen and paraffin-embedded tissues (Figure 1). At a higher-
power view, positive-granular immunoreactions were seen in
the perikaryon and dendrites of melanocytes. Follicular
melanocytes in the bulb also showed a positive reaction with
the MoAb (data not shown). In both frozen and paraffin
sections, no other cell types besides melanocytes in the skin
reacted positively with MoAb HMSA-5. Keratinocytes and
melanophages that contained melanosomes were negative for
immunoreaction, 'revealing dark green granules counter-
stained with methyl green. None of the other normal tissues
tested reacted with MoAb HMSA-5 (Table I).
Benign melanocytic nevi MoAb HMSA-5 reacted positively
with cells of both epidermal and dermal nevi. They showed50 J.E. DER et al.
Figure 1 Normal human adult skin stained with MoAb
HMSA-5 by the ABC technique, showing melanocytes along the
dermal-epidermal junction. The dendritic processes reveal immuno-
reactive granular materials (x 160).
granular cytoplasmic staining similar to that seen in normal
epidermal and follicular melanocytes. Dysplastic melanocytic
nevi (DMN) reacted strongly with MoAb HMSA-5. In der-
mal nevi, nests of cells close to the epidermis (which con-
tained numerous melanosomes) reacted more strongly than
did those nevus cells that were located in the middle or lower
part of the dermis (Figure 2).
Malignant melanoma All subtypes of human malignant mel-
anoma tested, e.g. superficial spreading melanoma (SSM),
lentigo maligna melanoma (LMM), and nodular melanoma
(NM), reacted positively with MoAb HMSA-5. In most
melanoma cells, the entire cytoplasm was filled densely with
strongly positive granules. In SSM, many large 'pagetoid'
cells located within the epidermis reacted with MoAb
HMSA-5 (Figure 3). In one SSM specimen a continuous
layer of MoAb HMSA-5 positive cells was seen along the
basement membrane of hair follicles, sebaceous glands and
their ducts (Figure 4).
Non-melanocytic tumours None of the tumours tested re-
acted with MoAb HMSA-5, including neural-crest derived
tumours.
Figure 2 Dysplastic melanocytic nevus stained with MoAb
HMSA-5, revealing highly positive large epithelioid cells near the
dermal-epidermal junction. ABC staining (x 160).
Cultured cells The reactivity of MoAb HMSA-5 was tested
with five human melanoma cell lines which included SK
Mel-23, SK Mel-28, SK Mel-118, HMV II, and G361. SK
Mel-28 HMV II, and G361 cultured cell lines did not pro-
duce much visible melanin pigments under our culture condi-
tions. MoAb HMSA-5 reacted homogenously with HMV II
and G361 cell lines. The highly pigmented, SK Mel-23 cells
reacted strongly, whereas SK Mel-118 amelanotic melanoma
cells showed a much lower reaction with MoAb HMSA-5. In
all of the positive-cell lines the immunostaining was granular
and located within the cytoplasm.
Immunoelectron microscopy
G361 human melanoma cells contained a large number of
melanosomes in early stages of development. These consisted
of both spherical melanosomes with microvesicular in-
clusions, and ellipsoidal melanosomes with lamellar internal
structure. In certain melanosomes both microvesicular and
lamellar matrix were seen. Other organelles within melanoma
cells included well developed Golgi complexes, endoplasmic
reticulum (ER), and mitochondria. Positive immunogold
reactivity were seen on small vesicles (about 20-40 nm)
which clustered mostly around early-stage melanosomes.
These vesicles appeared to be similar in structure to those
Table I Distribution of MoAb HMSA-5 reactive antigen in non-melanocytic and
melanocytic tissues and tumours in paraffin sections
Tissue Reactivity Tissue Reactivity
Normal tissue
Appendix - (0/2)a Gall bladder - (0/3)
Kidney - (0/2) Spleen - (0/3)
Placenta - (0/1) Fallopian tube - (0/2)
Prostate - (0/1) Lung - (0/1)
Stomach - (0/3) Fat tissue - (0/3)
Brain - (0/3) Conjunctiva - (0/1)
Liver - (0/2)
Neoplastic Tissue
Astrocytoma - (0/2) LMMb + (15/16)
Meningioma - (0/2) SSMC + (27/29)
Morton's neurinoma - (0/2) Nodular melanoma + (2/2)
Neurofibroma - (0/2) Metastatic melanoma + (3/4)
Neurilemmoma - (0/2) Nevi:
Lung carcinoma - (0/3) compound type + (10/10)
Colon carcinoma - (0/1) junctional type + (5/5)
SCCd - (0/1) dermal type + (5/5)
Teratoma - (0/6) dysplastic type + (15/15)
aNumbers in parentheses refer to the number ofpositive specimens/total number of
specimensstudied. bLMM -Lentigo malignamelanoma. CSSM -Superficial spreading
melanoma. dSCC - Squamous cell carcinoma of skin.HUMAN MELANOSOME SPECIFIC ANTIGEN (HMSA) 51
Figure 3 Superficial spreading melanoma (SSM) specimen
stained with MoAb HMSA-5, showing nests of positively stained
cells aligned along the dermal-epidermal junction. 'Pagetoid' cells
in the epidermis also reacted with HMSA-5. (x 160).
Figure 4 SSM specimen stained with MoAb HMSA-5, revealing
melanocytes located in the hair follicles (HF) and sebaceous
glands (SG) as a continuous layer a. Higher magnification of a
serial section through the same SSM specimen stained with
HMSA-5, showing positively stained tumour cell nests (TN) adja-
cent to the continuous layer of melanocytes (MC) bordering the
sebaceous gland and hair follicles. Melanophages (MP) are
stained dark, but they are negative b.
previously reported as vesiculoglobular bodies or micro-
vesicles within the melanosomes (Jimbow & Fitzpatrick,
1973). Immunogold particles were also seen on part of the
Golgi-ER complex while the nucleus, mitochondria, rough
ER, and most of the coated vesicles did not show a positive
immunogold reaction (Figure 5).
Antigen characterisation and the use ofinhibitors ofprotein
glycosylation
MoAb HMSA-5 immunoprecipitates from '25I-labelled ly-
sates of either surface-labelled or total cell homogenates of
G361 cells revealed a band with an approximate M, of
70 kDa on SDS-PAGE gels (Figure 6, panels a and b, lane
1). Relatively small amounts of antigen were detected after
the surface labelling (Figure 6, panel a, lane 1). This was
consistent with flow cytometry measurements of cell surface
HMSA-5 antigen expression using a fluorescein-labelled
secondary antibody (data not shown). When different
melanoma cell lines were compared, some small variations in
the M, of the antigen were seen on SDS-PAGE gels,
presumably due to different degrees of post-translational
modification.
When immunoprecipitation experiments were carried out
on cell lysates of G361 cells pre-treated for 12h with the
glycosylation inhibitors monensin or tunicamycin, some
differences in the autoradiographic gel profiles were seen
compared to controls, despite the fact that all experiments
were balanced for total radioactivity (see Materials and
methods). Monensin is a carboxylic acid ionophore which is
known to partially inhibit post-translational modifications
within the Golgi complex by disrupting proton gradients
necessary for vesicular transport (Griffiths et al., 1983).
Monensin caused an apparent increase in the amount of
immunoprecipitable antigen compared to controls in both
surface and total labelled cell lysates (Figure 6, panels a and
b, lane 2). Coincident with this apparent quantitative increase
was a slight decrease in the Mr of the immunoprecipitated
antigen, consistent with alterations in post-translational pro-
cessing. Tunicamycin is an analogue of N-acetyl-glucosamine
which prevents the correct assembly of oligosaccharide-lipids
necessary for co-translational N-glycosylation (Elbein, 1987).
When this inhibitor was used, there was a decrease in the
amount of immunoprecipitable antigen, particularly in the
total-labelled lysate immunoprecipitate (Figure 6, panel b,
lane 3) without an accompanying downward shift in the Mr
on SDS-PAGE.
Similar inhibitor experiments were carried out using a
biosynthetic radiolabelling protocol in which the inhibitors
were present during a 6 h pre-incubation as well as during a
6 h labelling period with 35S-methionine. When these
experiments were carried out and immunoprecipitates from
lysates balanced for total radioactivity were compared,
monensin again caused a slight decrease in the Mr of the
HMSA-5 antigen and a quantitative increase in its amount
compared to control (Figure 7, lanes 2 and 3). However,
when tunicamycin was used, MoAb HMSA-5 was unable to
immunoprecipitate any proteins detectable by SDS-PAGE
fluorography (Figure 7, lane 4).
Neither deoxynojirimycin or swainsonine, inhibitors of
early and late N-linked glycan processing (glucosidase 1 and
a-mannosidase II, respectively) (Elbein, 1987) had significant
effects on the Mr of the HMSA-5 antigen, although the
amount of immunoprecipitable antigen was decreased com-
pared to untreated cells (Figure 7, lanes 5 and 6). Brefeldin
A, which perturbs intracellular transport by blocking ER to
Golgi transport (Lippincott-Schwartz et al., 1989) gave a gel
profile for the antigen which is very similar to that seen with
monensin, i.e., a net accumulation of a slightly smaller M,
form of the molecule (Figure 7, lane 7).
Pulse-chase experiments
A pulse-chase time course experiment using 35S-methionine
was carried out to follow the biosynthesis of the HMSA-5
antigen. The antigen was readily precipitable at the 30 min
pulse (Oh chase) time point and had a Mr of 68-69kDa
(Figure 8). There was a very slight increase (1-2kDa) in the
Mr of the antigen over the first hour ofthe chase, after which
time the molecule maintained its Mr for the duration of the
time course. Since the cell lysates were balanced for radio-
activity, it was possible to compare semi-quantitatively the52 J.E. DER et al.
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Figure 5 Immunoelectron microscopic localisation of HMSA-5 antigen using a pre-embedding staining method with MoAb
HMSA-5 followed by protein A-colloidal gold (5 nm beads) in G361 human melanoma cells. a, Gold particles are associated with
small vesicles which interact with the outer melanosomal membrane (arrows) and also with Golgi cisternae which possibly give rise
to them (panel a, insert). x 18,000. b, Negative control using the protein A-gold alone. x 18,000. M: melanosome; GA: Golgi
apparatus; MT: mitochondria; N: nucleus; SV: small vesicles.
b
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Figure 6 Autoradiograms of SDS-PAGE profiles of surface vs
total cellular distribution of immunoprecipitated HMSA-5
antigen, as measured by vectorial iodination. G361 human
melanoma cells are labelled in vitro using two different procedures
for either intact cell surface labelling (a, surface) or cell lysate
labelling (b, total), lanes 1, 2 and 3 in both panels a and b
correspnd to control cells (lane 1), cells preincubated in 1O JM
monensin (lane 2) and cells preincubated in 10 tg ml -'
tunicamycin (lane 3).
amounts of antigen present at the different time points. It
was clear that the 16 h chase time point showed a marked
decrease in the intracellular quantity of the antigen and that
by 24 h the antigen band was hardly detectable on the
fluorograph of the SDS-PAGE gel. This result suggested that
the HMSA-5 glycoprotein is either rapidly turning over or is
being released by the cell, or is being processed within the
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.....-.... ..... .. kDaORSM
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Figure 7 Fluorograph of SDS-PAGE profiles of immuno-
precipitated HMSA-5 antigen after labelling G361 melanoma
cells with 35S-methionine. Cells were either untreated (lanes and
2) or treated with a variety of glycosylation or intracellular
transport inhibitors. The inhibitors used and their final concen-
trations were monensin 00 gAm (lane 3); tunicamycin jig ml-
(lane 4); deoxynojirimycin 2.5 mm (lane 4); swainsonine pg ml-'
(lane 6); brefeldin A 10;Lg ml-' (lane 7). Details of the preincuba-
tion and labelling protocol are described in Materials and
methods.
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Figure 8 Fluorograph of SDS-PAGE profiles of time course of
MoAb HSMA-5 immunoprecipitation during a pulse-chase
experiment using G361 human melanoma cells. Lane 0 represents
cells which were pulsed for 30 min and processed for immuno-
precipitation. The remaining lanes show the immunoprecipitates
obtained at the indicated chase time points (in hours). Lane C
shows the result of a control immunoprecipitation using pre-
immune mouse serum. All lysates were balanced for total
radioactive content prior to immunoprecipitation.
cell to a form that is no longer recognised by the MoAb. In
order to test the possibility that the antigen is being secreted
or shed, immuno-precipitation was carried out on the spent
culture supernatant from the previous cell labelling
experiments. The supernatants were collected, clarified by
centrifugation and processed for immunoprecipitation with
MoAb HMSA-5, as described for cell lysates. In every case
the SDS-PAGE fluorographs did not reveal any appreciable
HMSA-5 antigen band, even in supernatants from the 16 and
24 h time points when it was known that the intracellular
amounts of the antigen had decreased significantly (data not
shown).
Enzyme studies
Since it was known that tunicamycin had an effect on the
immunoreactivity of the HMSA-5 antigen, it was impossible
to identify the core unglycosylated protein by direct
biosynthesis/inhibitor immunoprecipitation methods. In or-
der to determine the degree of N-linked glycosylation of this
antigen, immunoprecipitates of mature, fully glycosylated
HMSA-5 antigen were digested with the enzyme N-glycanase,
which removes virtually all types of N-linked glycan moieties
(see Materials and methods). Over the duration of the diges-
tion period, the M, antigen decreased from 70 kDa to
approximately 60 kDa (Figure 9). This provides evidence that
the antigen contains 3 to 5 N-linked oligosaccharide chains,
based on a reported 2-4 kDa shift per N-linked saccharide
moiety on SDS-PAGE gels (Lewis et al., 1985).
Early in our studies several factors had pointed towards
the possibility of the HMSA-5 antigen being the enzyme
tyrosinase. Firstly, the immunogen used to raise the antibody
was purified melanosomes, known to contain high levels of
this enzyme. Secondly, the Mr of the antigen was similar to
reported values for SDS-PAGE mobilities of tyrosinase
(Imokawa, 1990). Thirdly, when immunoprecipitation was
carried out on lysates of "5S-methionine-labelled B16-FIO
mouse melanoma cells, a weak band at 69-70 kDa was
detected on SDS-PAGE fluorographs (data not shown). The
fact that the HMSA-5 antigen was strongly conserved across
species barriers, again was indicative of an important con-
served protein such as tyrosinase (Hearing & Jimenez, 1989).
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Figure 9 Fluorograph ofSDS-PAGE profiles of a time course of
N-glycanase digestion of immunoprecipitated HMSA-5 antigen.
35S-methionine-labelled immunoprecipitate was processed for
digestion with the enzyme N-glycanase. Eight identical aliquots of
antigen were prepared and enzyme was added to seven of these
and incubated for the indicated times (in hours). A control
aliquot (C) was indicated for the duration of the 16h, in the
absence of enzyme. One of the 16 h incubations with the enzyme
had a second aliquot ofenzyme added at the 8 h time point (x 2)
to avoid the possibility of insufficient enzyme for full digestion.
In order to examine this possibility, HMSA-5 immuno-
precipitates from SK MEL 23 human melanoma cells were
resolved on non-denaturing PAGE gels and these were
incubated in 0.1% (w/v) dopa in phosphate buffer, pH 7.0.
Control lanes containing tyrosinase extracts gave a positive
dark brown band in the 60-70 kDa Mr region of the gel,
whereas the HMSA-5 lanes failed to show this tyrosinase
positive reaction (data not shown).
Another antigen, derived from melanosomes, which had
been reported in the literature was the gp75 pigmentation-
associated antigen (Thomson et al., 1985). Since the Mr of
this antigen was similar to that recognised by MoAb HMSA-
5, parallel immunoprecipitations with HMSA-5 and MoAb
TA99 (which recognises gp75) were carried out (data not
shown). Although the results obtained suggested that both
antibodies were recognising a common antigen, it was
difficult to make a definite conclusion based on the Mr of the
two antigens since it was known that several other antigens,
including tyrosinase, albumin, and the silver locus human
homologue protein (Kwon et al., 1987a; Chintamaneni, 1991)
also migrate into this region of SDS-PAGE gels. Parallel
sequential immunodepletion experiments showed that MoAb
HMSA-5 was able to pre-clear the labelled antigen recog-
nised by MoAb TA99 and vice versa (Figure 10). After four
rounds of immunoprecipitation with one antibody, the other
antibody was not able to immunoprecipitate a 69-70 kDa
band (Figure 10, see arrows). An alternative procedure to
test the identity of the recognised antigens involving partial
peptide mapping with two different proteases; trypsin and
V-8 protease was also carried out. Biosynthetically labelled
SK Mel 23 melanoma cells were processed for immuno-
precipitation with MoAbs HMSA-5 and TA99. These
immunoprecipitates were processed for partial peptide map-
ping as described in the Materials and methods sections and
the digestion patterns were compared (Figure 11). The diges-
tion patterns and the peptide fragments obtained for the two
antigens were identical, for both proteases used, suggesting
that the two antibodies recognise a common glycoprotein.
Discussion
Several studies have reported the development of murine
MoAbs against human melanosomes by immunising animals54 J.E. DER et al.
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Figure 10 Fluorograph of SDS-PAGE profiles of a sequential immunodepletion experiment. A IIS-labelled lysate of G361
melanoma cells was precleared as described in Materials and methods. The lysate was divided into two aliquots and sequentially
immunoprecipitated four times with MoAb HMSA-5 (lanes 1-4) or MoAb TA99 (lanes 7-10), followed by one round with
secondary antibody (goat anti-mouse) and protein A-Sepharose (GAM-PrA; lanes 5 and 1) and finally immunoprecipitated with
either MoAb TA99 (lane 6) or MoAb HMSA-5 (lane 12).
with intact human melanoma cells or with melanosomes
derived from these cells (McEwan et al., 1989; Hayashibe et
al., 1986). Four MoAbs, HMSA-1 to 4, previously developed
by the latter method in this laboratory (Akutsu & Jimbow,
1986; Maeda & Jimbow, 1988; Jimbow et al., 1990) were
shown to recognise melanosomal antigens highly specific to
neoplastic melanocytes. MoAb HMSA-5, described in this
report, was generated against melanosomes isolated from
cultured human foreskin melanocytes, grown in the presence
of TPA. The antigen recognised by MoAb HMSA-5 is pre-
served when melanocytes proliferate forming benign neo-
plastic lesions, as well as when the melanocyte progressively
becomes malignant. In one SSM specimen, strong evidence
was found to suggest that malignant melanoma may progress
into the dermis along the skin appendages, such as hair
follicles and sebaceous glands (Figure 4a). MoAb HMSA-5 is
an extremely useful antibody for immunohistochemistry of
pigmented cells since it reacts strongly with both frozen and
paraffin-embedded specimens.
The pattern of MoAb HMSA-5 reactivity is distinct from
that described previously with MoAbs HMSA 1 and 2, which
recognise antigens present only on melanocytes which have
undergone malignant transformation (Jimbow et al., 1990).
HMSA-5 antigen was not detected on pigment granules when
transferred to keratinocytes in the epidermis, nor was it seen
within melanophages present in the dermis. Both of these
observations are consistent with the notion of MoAb
HMSA-5 identifying an epitope which is transiently ex-
pressed in immature, melanosomes and perhaps lost or
masked on the mature melanosomes.
The glycosylation inhibition studies with tunicamycin and
monensin indicated a role for N-linked saccharide residues in
the formation or folding of the HMSA-5 epitope. In the
absence of N-linked glycans, the antigenic determinant was
presumably lost, either due to induced changes in the folding
of the protein or because the oligosaccharide side-chains
themselves were the epitopes. The most likely explanation for
the detection of immunoprecipitable HMSA-5 antigen in the
'25I-labelled tunicamycin-treated cell lysates (Figure 6, panels
a and b, lane 3) is that the 12 h pre-incubation with
tunicamycin was not sufficiently long to ensure that all of the
HMSA-5 antigen within the cell lacked N-linked glycans.
Any residual molecules of fully N-glycosylated HMSA-5
antigen which had not 'turned over' and were still present
could still be immunoprecipitated by the antibody. Since the
intensity of the HMSA-5 antigen signal is similar in the
control and tunicamycin-treated samples in the surface-
labelling experiment (Figure 6, panel a, lanes 1 and 3), it
might suggest that the residual HMSA-5 antigen which
accounts for the autoradiographic signal is largely due to
surface-expressed molecules.
At least two possible explanations can be offered to
account for the accumulation of the antigen in response to
monensin treatment. One effect of monensin might be to
block the normal shedding or secretion of the antigen into
the culture supernatant. Alternatively, the epitope detected
by HMSA-5 might be present only transiently on a post-
translational intermediate in the synthesis of a molecule
which, when mature, is no longer reactive with the MoAb.
The monensin blockade might allow the accumulation of this
intermediate by inhibiting its conversion to a mature non-
reactive species. Monensin has been reported to cause an
immediate increase in melanogenesis as measured by a 10-
fold increase in tyrosinase activity and much higher
melanosome maturation index (Oikawa, 1987). This effect
was not dependent on de novo protein synthesis and was
attributed by the authors to an ionophore effect of the drug
which led to increased neutralisation of the melanosome and
a resultant increase in tyrosinase activity. Perhaps the same
monensin-triggered mechanism which allows increased mela-
nosome maturation, causes an increase in the amount of
immunoprecipitatble HMSA-5 antigen.
Both MoAb HMSA-5 and MoAb HMSA-1 exhibited
strong cytoplasmic reactivity with similar density by immuno-HUMAN MELANOSOME SPECIFIC ANTIGEN (HMSA) 55
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Figure 11 Fluorograph of SDS-PAGE profiles of partial proteo-
lytic maps of HMSA-5 and TA99 antigens using trypsin (panel a)
or V8 protease (panel b). 35S-methionine labelled HMSA-5 and
TA99 immunoprecipitates were processed for partial proteolytic
cleavage using either trypsin or V8 protease, as described in
Materials and methods (enzyme treatments). In panel a,
undigested HMSA-5 and TA99 antigens can be seen to approx-
imately 70 kDa while the lower Mr digestion products are
indicated by arrows. In panel b, the untreated HMSA-5 and
TA99 antigens are shown in lane 1, while the proteolytic products
are indicated by the lower arrows in lanes 2 and 3. Lane 2
contains 10-fold more enzyme (5 mg) than lane 3 (0.5 mg) in both
cases.
histochemistry on serial stained melanoma sections (data not
shown). A possibility that the two MoAbs recognise the same
(or similar) subcellular components was excluded by
immunoelectron microscopy. MoAb HMSA-5 reacted with a
part of the Golgi complexes and the melanosome-associated
microvesicles whereas MoAb HMSA-1 reacted directly with
the melanosomal inner matrix (Akutsu & Jimbow, 1988).
The HMSA-5 antigen showed homology with the antigen
recognised by MoAb TA99 as tested by sequential immuno-
depletion and by partial peptide mapping of the immuno-
precipitated proteins. MoAb TA99 identifies an antigen gp75
(Thomson et al., 1985; Tai et al., 1985) 'pigmentation-
associated-antigen' (PAA), which was originally described as
an antigen immunoprecipitated by serum from a melanoma
patient (Mattes et al., 1983). PAA was shown to be present
in both melanocytes and melanoma cells (Tai et al., 1983;
Houghton et al., 1987). In addition, an inverse correlation
between expression of the TA99 antigen and the stage of
progression of melanoma tumours was observed (Houghton
et al., 1987). Its glycosylation characteristics suggested that
this antigen is processed in the trans-Golgi cisternae prior to
its localisation on melanosomes (Roux & Lloyd, 1986;
Vijayasaradhi & Houghton, 1991).
Immunoelectron microscopy using MoAb TA99 demon-
strated a peripheral pattern of reactivity with the outer mem-
brane of mature melanosomes, and little or no reactivity with
other organelles (Thomson et al., 1988). MoAb HMSA-5,
like MoAb TA99, showed strong ractivity with the cytoplas-
mic face of the melanosome, but in addition appeared to
react positively with small associated uncoated vesicles and
regions of the Golgi complex from which these vesicles
presumably originate.
A recent study using MoAb TA99 has shown very similar
results to those described here with regard to some aspects of
the biosynthesis, turnover and glycosylation of gp75 (Vi-
jayasaradhi et al., 1990). However, these authors consistently
detect two discrete forms of the mature gp75 molecule with
MoAb TA99. They propose the existence of alternatively
glycosylated mature forms of the molecule, or alternatively
spliced transcripts of the gene leading to two different
polypeptides, to explain their results. In contrast, MoAb
HMSA-5 appears to immunoprecipitate only one mature
form of gp75.
Researchers using another antibody, MoAb 2GI0, which
has reactivity against gp75 (Cuomo et al., 1991) have recently
described their detection of plasma membrane localised gp75
by surface iodination and proteolysis studies (Giacomini et
al., 1992). Their results is in strong agreement with our
vectorial iodination data which showed modest amounts of
HMSA-5 precipitable gp75 being labelled on the cell surface.
Researchers attempting to clone the gene for murine
tyrosinase by immunological screening of cDNA expression
libraries (Jackson, 1988) or by differential hybridisation
between murine melanoma and neuroblastoma cDNA lib-
raries (Shibahara et al., 1986), isolated several clones which
did not map to the c-locus (color; tyrosinase) on mouse
chromosome 7 as expected (Jackson, 1988; Kwon et al.,
1987b; Kwon et al., 1989).. Instead, these clones mapped at
the b (brown) locus on mouse chromosome 4 and encoded a
protein which had limited homology (40-50%) with murine
tyrosinase (Jackson, 1988; Shibahara et al., 1986; Kwon et
al., 1989). Peptide sequencing of affinity-purified human
TA99 antigen showed 90% identity with regions of the
deduced amino acid sequence of one of these murine clones
pMT4 (Vijayasaradhi et al., 1990). When oligonucleotide
probes based on this gp75 amino acid sequence information
were used to screen a human melanoma cDNA library, a
clone termed GP 75-1 was isolated. It is believed that this
clone encodes the human counterpart of the murine b-locus
gene product (Vijayasarshi et al.,1990). At the same time, the
full nucleotide sequence encoding human tyrosinase-related
protein (TRP) was reported and is believed to be identical to
the b-locus gene (Cohen et al., 1990).
The mouse b locus gene mapped to mouse chromosome 4
and its genomic organisation has been analysed (Shibahara et
al., 1991) while the human homologue, termed CAS2, has
been mapped to human chromosome 9p22-pter (Chinta-
maneni et al., 1991). Other workers have demonstrated that
the gp75/b-locus/TRP protein has a measurable catalase
activity and have speculated on the role for such an enzyme
in controlling pigment production in mammals (Halaban &
Moellmann, 1990). Alternative suggestions for the functional
identity of the b-locus gene product are two other enzymes
involved in post-tyrosinase regulation of melanogenesis;
namely 5,6 dihydroxyindole conversion factor and dopa-
chrome oxidoreductase (Muller et al., 1988; Jackson, 1988).
Although it does appear to play a regulatory role in
melanogenesis as shown by retroviral infection with the
murine b locus gene (Bennett et al., 1990), its exact function
remains to be elucidated.
During the characterisation of MoAb HMSA-5 described
in this report, we found that it may recognise the same
glycoprotein as MoAb TA99 and could therefore be a useful
reagent for analysing gp75 expression. MoAb HMSA-5
reacts with some melanoma cell lines (including G361) which
are amelanotic under our culture conditions, whereas MoAb
TA99 is reportedly only reactive with melanised, differ-
entiated melanoma cells (Vijayasardhi & Houghton, 1991). In
addition, MoAb TA99 was reported to react weakly with
keratinocytes adjacent to melanocytes in both fetal and adult
skin (Thomson et al., 1985) whereas MoAb HMSA-5 re-
activity is restricted to the melanocytes. Both of these obser-
vations may be due to differences in the epitopes recognised
by the two antibodies on a common target glycoprotein. In
the latter observation, it may be that the TA99 epitope is
partially retained after transfer of melanosomes to keratino-
cytes, whereas the HMSA-5 epitope is masked or lost. If so,
the two antibodies might ideally be used in conjunction with
one another to study the b-locus gene product expression and
distribution in both normal and neoplastic melanocytes.
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